eXoZymes Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $3.31
- 52-Week Range
- $2.93 – $16.90
- Market Cap
- $32.38M
- P/E (TTM)
- —
- EPS (TTM)
- -1.16
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 8.49
- PEG Ratio
- —
- Return on Equity
- -187.16%
- Return on Assets
- -74.74%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 3.81
- Debt/Equity
- 0.30
- Total Debt
- $1.09M
- Free Cash Flow
- $-3.25M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $30.98M
Market Snapshot
About
eXoZymes Inc. is a biotechnology company developing novel enzyme therapies for rare genetic diseases and other serious medical conditions. The company's therapeutic approach focuses on creating enzyme replacement therapies and enzyme-based treatments that address underlying disease mechanisms. eXoZymes is advancing a pipeline of product candidates targeting metabolic disorders, genetic diseases, and other conditions where enzyme deficiencies or dysfunctions play a critical role. The company conducts research and development activities aimed at bringing innovative biologic therapies to patients with limited treatment options.